Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Astec Lifesciences Ltd (ASTEC) is currently trading at 660.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Astec LifeSciences Ltd is primarily engaged in the manufacturing of agrochemicals and pharmaceutical intermediates, offering active ingredients, intermediates, and formulations mainly for crop protection and API manufacturers. The company expanded its operations significantly over the years, reaching an installed production capacity of 3150 MT, as of FY 2009-10. This expansion included acquiring new plots and establishing multiple manufacturing units. Astec LifeSciences has built strategic relationships with major multinationals like Syngenta and Nufarm, indicating strong integration into the global agrochemical supply chain. In 2015, Godrej Agrovet Limited acquired a major stake in the company, making Astec LifeSciences a subsidiary, which led to enhanced investment and growth opportunities. Recently, the company has focused on innovation, inaugurating the Adi Godrej Centre for Chemical Research and Development in 2023, indicating a drive towards advanced R&D capabilities.
Over the past 52 weeks, Astec Lifesciences Ltd has traded between a low of ₹512.35 and a high of ₹936.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Astec Lifesciences Ltd has a market capitalization of approximately 1,505.43. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Astec Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -22.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,505.43 Cr, Astec Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Astec Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Astec Lifesciences Ltd is -22.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Astec LifeSciences reported a consolidated net loss of ₹18.78 crore for Q1 FY27 (quarter ended June 30, 2026).
Astec LifeSciences Ltd is primarily engaged in the manufacturing of agrochemicals and pharmaceutical intermediates, offering active ingredients, intermediates, and formulations mainly for crop protection and API manufacturers.
The company expanded its operations significantly over the years, reaching an installed production capacity of 3150 MT, as of FY 2009-10. This expansion included acquiring new plots and establishing multiple manufacturing units.
Astec LifeSciences has built strategic relationships with major multinationals like Syngenta and Nufarm, indicating strong integration into the global agrochemical supply chain.
In 2015, Godrej Agrovet Limited acquired a major stake in the company, making Astec LifeSciences a subsidiary, which led to enhanced investment and growth opportunities.
Recently, the company has focused on innovation, inaugurating the Adi Godrej Centre for Chemical Research and Development in 2023, indicating a drive towards advanced R&D capabilities.
Fertilizers & Agrochemicals
Pesticides & Agrochemicals
1,472 Cr
Low Risk
-22.1
20.2
—
3.9
936.00
512.35
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
3
Neutral
7
Bullish
4
Bearish
16
Neutral
7
Bullish
23
Bearish
13
Neutral
0
Bullish
19
Bearish
3
Neutral
7
Bullish
4
Bearish
3
Neutral
7
Bullish
4
Bearish
13
Neutral
0
Bullish
19
Bearish
13
Neutral
0
Bullish
19
Bearish
13
Neutral
0
Bullish
19
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1127.00 | 1,877 Cr | 13.10 | 1.47 | 0.04 | 11.43 | 15.51 | 10.00 | ||
595.10 | 1,726 Cr | 13.79 | 1.41 | 0.34 | 11.42 | 14.78 | 6.26 | ||
132.95 | 1,523 Cr | 14.14 | 1.51 | 0.57 | 11.86 | 15.46 | 8.06 | ||
668.15 | 1,505 Cr | -22.61 | 3.85 | 0.00 | -20.72 | -5.54 | -7.07 | ||
59.75 | 1,497 Cr | 23.31 | 0.97 | 0.00 | 1.86 | 6.75 | 2.13 | ||
1038.60 | 1,265 Cr | 19.34 | 2.99 | 0.29 | 15.10 | 17.43 | 7.95 | ||
266.50 | 901 Cr | 14.97 | 2.01 | 0.00 | 12.17 | 15.44 | 7.15 | ||
| Median: 7 Co. | — | 595.10 | 1,505 Cr | 14.14 | 1.51 | 0.04 | 11.43 | 15.44 | 7.15 |
